other material
confidence high
sentiment neutral
materiality 0.60
Provectus converts $2.13M in director fees to Series D-1 Preferred shares
PROVECTUS BIOPHARMACEUTICALS, INC.
- Converted $2,131,838.75 in accrued directors’ fees into 744,878 shares of Series D-1 Preferred at $2.862 per share.
- Preferred shares are convertible into 7,448,780 shares of common stock.
- Issuance covers fees owed through September 30, 2024; not under 2024 Equity Compensation Plan.
- Board approved on August 14, 2024; fees had been accruing since April 2017.